- Home
- AGMH vs EDSA Comparison
AGMH vs EDSA Comparison
Compare AGMH & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- EDSA
- Stock Information
- Founded
- AGMH 2015
- EDSA 2015
- Country
- AGMH Hong Kong
- EDSA Canada
- Employees
- AGMH N/A
- EDSA N/A
- Industry
- AGMH EDP Services
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- EDSA Health Care
- Exchange
- AGMH Nasdaq
- EDSA Nasdaq
- Market Cap
- AGMH 17.1M
- EDSA 17.5M
- IPO Year
- AGMH 2018
- EDSA N/A
- Fundamental
- Price
- AGMH $6.87
- EDSA $2.82
- Analyst Decision
- AGMH
- EDSA Strong Buy
- Analyst Count
- AGMH 0
- EDSA 2
- Target Price
- AGMH N/A
- EDSA $13.00
- AVG Volume (30 Days)
- AGMH 12.0M
- EDSA 110.6K
- Earning Date
- AGMH 11-18-2025
- EDSA 08-08-2025
- Dividend Yield
- AGMH N/A
- EDSA N/A
- EPS Growth
- AGMH N/A
- EDSA N/A
- EPS
- AGMH 6.43
- EDSA N/A
- Revenue
- AGMH $32,044,575.00
- EDSA N/A
- Revenue This Year
- AGMH N/A
- EDSA N/A
- Revenue Next Year
- AGMH N/A
- EDSA N/A
- P/E Ratio
- AGMH $1.11
- EDSA N/A
- Revenue Growth
- AGMH N/A
- EDSA N/A
- 52 Week Low
- AGMH $1.09
- EDSA $1.55
- 52 Week High
- AGMH $107.50
- EDSA $4.49
- Technical
- Relative Strength Index (RSI)
- AGMH 56.76
- EDSA 62.43
- Support Level
- AGMH $7.59
- EDSA $2.47
- Resistance Level
- AGMH $9.49
- EDSA $2.82
- Average True Range (ATR)
- AGMH 1.98
- EDSA 0.17
- MACD
- AGMH -0.07
- EDSA 0.03
- Stochastic Oscillator
- AGMH 28.82
- EDSA 81.44
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an integrated technology company. The company focuses on blockchain-oriented ASIC chip design, high-end crypto miner production, and fintech technology software services. The company generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.